HCV Clinical Trial
Official title:
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With Hepatitis C Viral Infection Treated by Direct Acting Antiviral Drugs
1. Study Changes in lipid profile and the impact of Insulin resistance on virological
response in patients with Hepatitis C viral infection treated by Direct Acting Antiviral
agents
2. The assessment of serum vitamin D levels in HCV infected patients and predictive value
of pre-treatment serum vitamin D level for achieving sustained virological response at
12 weeks post-treatment
Patients and methods:
This cross-sectional study will include 100patients of chronic HCV infection who attend El
Raghy Assiut university Hospital, either inpatients or outpatients. Chronic HCV infection
will be diagnosed based on detectable HCV RNA with anti-HCV Ab in patient with clinical
and/or ultrasonographic criteria of chronic liver disease.
Patients will receive treatment to HCV by DAAs and follow up for 12 weeks to confirm
sustained virological response
Method:
Patients presenting in this study will be subjected to the following:
1. Full history and clinical evaluation.
2. Body weight (kg) and height (m).
3. BMI will calculate as weight divided by squared height (kg/m2).
4. Waist circumference will measured at a level midway between the lowest rib and the iliac
crest, and the hip circumference at the level of the great trochanters, with the legs
close together.
5. Blood pressure (mmHg) was measured twice in the upper arm after a 10-min period of rest
and taken an average.
Laboratory investigations will include:
- Complete blood count (CBC)
- Liver function test
- HCV Ab and HCV RNA by PCR
- HBs Ag
- Alpha fetoprotein
- Lipid profile
- Serum urea and creatinine
- Fasting blood sugar (FBG)and Serum fasting insulin level
- Insulin resistance determined via Homeostasis Model Assessment (HOMA-IR) IR = fasting
insulin (µu/ml) × fasting glucose (mmol/L)
----------------------------------------------------------------- 22.5 An index value of
˃ 2. 5 was defined as IR (Huang et al., 2011)
- Vitamin D level:
Vitamin D deficiency wasdefined as a 25 (OH)-vitamin D serum level < 20 ng/mL, vitaminD
insufficiency as 25 (OH)-vitamin D levels of 20 - 29.9ng/mL, and normal vitamin D levels ≥ 30
ng/mL (Holick MF et al.,2011)
- Abdominal Ultrasound
- Electrocardiogram (ECG)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05942937 -
National Prisons Hepatitis Education Project: Research Evaluation
|
N/A | |
Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Recruiting |
NCT05794646 -
Community Intervention to Eliminate HCV Among People Who Use Drugs.
|
N/A | |
Completed |
NCT04971330 -
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
|
||
Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
Active, not recruiting |
NCT03981445 -
Integrated HIV Prevention and HCV Care for PWID
|
N/A | |
Completed |
NCT02452814 -
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
|
N/A | |
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Not yet recruiting |
NCT06316739 -
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
|
N/A | |
Completed |
NCT02116543 -
TD-6450 MAD Study in HCV Infected Subjects
|
Phase 1 | |
Recruiting |
NCT05454579 -
The South-East Asian Transgender Health Cohort
|
||
Active, not recruiting |
NCT03221309 -
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
|
||
Completed |
NCT03801707 -
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
|
Phase 2/Phase 3 | |
Completed |
NCT01074008 -
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
|
Phase 2 | |
Completed |
NCT05616598 -
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
|
Phase 2/Phase 3 | |
Recruiting |
NCT05854511 -
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
|
Phase 3 | |
Completed |
NCT03069001 -
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV
|
Phase 4 | |
Completed |
NCT01842451 -
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
|
Phase 2 |